8299307777

Farm Przegl Nauk, 2010, 6

Praca finansowana przez Uniwersytet Medyczny

w Łodzi w ramach prac własnych nr 502-13-702

Piśmiennictwo

1.    Kratz F i wsp. Prodrugs strategies in anticancer chemo-therapy. Chem Med Chem 2007: 3: 20-53.

2.    Khandare J, Minko T. Polymer-drug conjugates: Progress in polymeric prodrugs. Próg Polym Sci 2006; 31: 359-397.

3.    Avendano C. Menendez CJ. Medicinal Chemistry of Anticancer Drugs. ElsevierB.V. Oxford 2008.

4.    Duncan R. Poły mer conjugates as anticancer nanomedi-cines. Naturę Rev Cancer 2006; 6: 688-701.

5.    Ehira C i wsp. Covalent Polymer-Drug Conjugates. Molecules 2005; 10: 114-125.

6.    Nevozhay D i wsp. Współczesny stan badań nad ko-niugatami i innymi systemami dostarczania leków w leczeniu schorzeń nowotworowych i innych jednostek chorobowych. Post Hig Med Dośw 2007; 61: 350-360.

7.    Duncan R. Polymer conjugates for tumor targeting and intracytoplasmic deliveiy. The EPR effect as a common gateway? PSTT 1999; 2: 441-449.

8.    Ulbrich K, Śubr V. Polymeric anticancer dmgs with pH-controlled activation. Adv Drug Deliv Rev 2004; 56: 1023-1050.

9.    Maeda H i wsp. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rei 2000; 65: 271-284.

10.    Kopećek J. Water soluble polymers in tumor targeted deliveiy. J Control Rei 2001; 74: 147-158.

11.    Duncan R i wsp. Preclinical evaluation of polymer-bound doxorubicin. J Control Rei 1992: 19: 331-346.

12.    Minko T. Kopećkova P. Kopećek J. Chronić exposure to HPMA copolymer-bound adriamycin does not induce multi drug resistance in a human ovarian carcinoma celi linę. J Control Rei 1999; 59: 133-148.

13.    Vasey PA i wsp. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methaciylamide copolymer doxorubicin]: first member of a new class of chemothcrapeutic agents. Drug-polymer conjugates. Clin Cancer Res 1999; 5: 83-94.

data otrzymania pracy: 15.02.2010 r. data akceptacji do druku: 09.04.2010 r.

14.    Thomson AH i wsp. Population pharmacokinetics in phase I drag development: a phase I study of PK1 inpa-tients with solid tumors. Br J Cancer 1999; 81: 99-107.

15.    Li Ch, Wallace S. Polymer-drug conjugates: Recenl de-velopment in clinical oneology. Adv Drag Deliv Rev 2008; 60: 886-898.

16.    Seymour LW. Hepatic Drag Targeting: Phase I Evalua-tion of Polymer-Bound Doxorabicin J Clin Oneol 2002; 20: 1668-1676.

17.    Schoemaker NE i wsp. A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. Br J Cancer 2002; 87: 608-614.

18.    Bisset D i wsp. Phase I and pharmacokinetic study of MAG-CPT (PNU166148): a polymeric derivative of camptothecin (CPT). Br J Cancer 2004; 91: 50-55.

19.    http://uwwaccesspharma.com ProLindae Fact Sheet 2009.

20.    Gieenwald RB i wsp. Effective drug deliveiy by PEGylated drag conjugates. Adv Drag Deliv Rev 2003; 55:217-250.

21.    Pasut G. Veronese FM. PEG conjugates in clinical de-velopment or use as anticancer agents: an overview. Adv Drag Deliv Rev 2009; 61: 1177-1188.

22.    Choe YH i wsp. Anticancer drag delivety Systems: Multi-loaded A ^J-acylpoly(ethylenr glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J Control Rei 2002; 79: 55-70.

23.    Abuchowski A i w sp. Alteration of immunological proper-ties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1997; 252: 3578-3581.

24.    Greenwald RB. PEG drugs: an overview. J Control Rei 2001; 74: 159-171.

25.    Graham ML. Pegaspargase: a review of clinical studies. Adv Drag Deliv Rev 2003; 55: 1293-1302.

26.    Branton LL, Lazo JS, Paiker KL. Goodman&Gilman’s The Pliarmacological Basis of Therapeutics. Mc Graw-HiU, USA 2006.

27.    Sapra P i wsp. Novel deliveiy of SN-38 markedly inhibits minor growth in xenografts including a Camptothecin-11 refractory model. Clin Cancer Res 2008; 14: 1888-1896.

28.    Li Ch. Poly(L-glutamic acid)-anticancer drag conjugates. Adv Drag Deliv Rev 2002; 54: 695-713.

29.    www.cclltherapeutics.com Opaxio (Xyotax) Fact Sheet 2009.

Adres do korespondencji:

Andrzej Stańczak

Zakład Farmacji Szpitalnej Wydziału Farmaceutycznego UM w Łodzi,

ul. Muszyńskiego 1, 91-151 Łódź;

tel.: [phone]

e-mail: [e-mail]

18